Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.Across the 68 markets, sales ...

RAs, originally for diabetes, may impact brain health, finding potential benefits for dementia and addiction but inconsistent ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small ...

A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Dr. Corey L. Hartman tells ESSENCE how this prescription can have long-term effects not just the body—but also on our skin.

Learn about what foods to avoid with type 2 diabetes. When a person is fasting, their blood glucose levels decrease. This triggers the pancreas to make and release more glucagon, a hormone that ...

HealthDay News — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without ...

A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...

RAs, and DPP-4is may offer benefits for patients with COPD, but clinical evidence comparing their effectiveness in reducing ...

Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes ...

Conventional markers used for diagnosing and managing diabetes have recently come to question. This blog addresses some of ...